Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High on Analyst Upgrade

Pulse Biosciences, Inc (NASDAQ:PLSE) hit a new 52-week high during trading on Monday after Canaccord Genuity Group raised their price target on the stock from $58.00 to $74.00. Canaccord Genuity Group currently has a buy rating on the stock. Pulse Biosciences traded as high as $58.94 and last traded at $56.8660, with a volume of 65,842 shares changing hands. The stock had previously closed at $53.29.

Several other research firms have also weighed in on PLSE. Mizuho set a $65.00 target price on shares of Pulse Biosciences in a report on Friday. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Needham & Company LLC upped their price target on Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a report on Friday. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Finally, Oppenheimer boosted their target price on Pulse Biosciences from $35.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pulse Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $66.60.

Insider Activity at Pulse Biosciences

In related news, COO Liane Teplitsky purchased 1,001 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was purchased at an average cost of $49.95 per share, with a total value of $49,999.95. Following the completion of the acquisition, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders purchased a total of 4,095 shares of company stock worth $199,931 in the last three months. 74.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC boosted its holdings in Pulse Biosciences by 844.6% during the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock worth $31,000 after buying an additional 549 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Pulse Biosciences during the 2nd quarter valued at $28,000. Axxcess Wealth Management LLC purchased a new stake in Pulse Biosciences during the 3rd quarter worth about $242,000. Bender Robert & Associates purchased a new stake in shares of Pulse Biosciences during the third quarter worth about $379,000. Finally, Jupiter Topco LLC acquired a new position in Pulse Biosciences in the 2nd quarter valued at $241,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Trading Up 5.8%

The business has a 50 day simple moving average of $51.55 and a 200-day simple moving average of $32.28. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of -47.17 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.52 million. Pulse Biosciences had a negative return on equity of 101.91% and a negative net margin of 5,603.88%. The company’s quarterly revenue was down 54.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.29) earnings per share. Research analysts predict that Pulse Biosciences, Inc will post -1.34 EPS for the current year.

Pulse Biosciences Company Profile